Key Drivers
- Strong liquidity
- Margin pressure
- Rising leverage
AIAI Summary
ITGR should be viewed as a “show-me” medtech name rather than a dependable compounder: with flat revenue, lower margins, and thin free cash flow, the stock likely needs clear evidence of sustained operating improvement and better cash conversion before its current valuation looks justified, especially amid strategic-review and governance/legal overhangs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Margin pressure
- •Rising leverage
ITGR is a mixed hold: liquidity and profitability are still decent, but weaker Q1 margins and cash flow, rising leverage, and a heavy intangible asset mix make the stock look expensive.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Base holding
- •Breakout test
ITGR's price action over the last month is mildly bullish, with higher highs/lows, a solid base in the low-90s, and a breakout attempt just above $94–$95 that still needs confirmation.
Sharp drop from the 2026-06-09 peak to the 2026-06-17 low signals short-term volatility
Sentiment & News
Key News Insights:
- •Q2 webcast scheduled
- •Results not released
- •Operating update focus
Integer Holdings announced it will host an Aug. 6 webcast to review Q2 2026 results and business highlights, with no new financial figures disclosed yet.
This is a routine earnings preview that should have limited immediate impact while setting expectations for the upcoming results discussion
Similar Companies in Healthcare
Other companies in the same sector with AI ratings